Zeev Zehavi

Since joining Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 1999 as Vice President Venture Investments, Zeev has held multiple positions within the organization.
From 2007-2015, Zeev served as the JJDC European representative out of Belgium, covering investments across Europe and Israel for all Johnson & Johnson sectors including Pharmaceuticals, Medical Devices and Consumer.
Working closely with Med Tech and Janssen R&D leadership, Zeev has built an innovative portfolio that has resulted in numerous onboardings creating growth engines for J&J and successful exits delivering strong returns for the JJDC and the sector portfolios.
Notable transactions include: Genmab (Darzalex), OrthoTaxy (Velys), Mazor, OrthoSpin, Movetis and FutuRX, an Israeli incubator for early stage Biotech opportunities.
Prior to joining JJDC, Zeev spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America.
He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years, leading private equity investments in companies within areas of Generic R&D, Drug delivery, Chiral chemistry, and a large Public Commercial US entity.
Zeev has retired from JJDC in December of 2022 and serves as a consultant to Alive Israel HealTech Fund and as Independent Industry expert board member in several companies in the field of Life Sciences.
Zeev holds a Bachelor of Science degree from the Hebrew University of Jerusalem and a Master of Business Administration degree in Marketing and Finance from Tel Aviv University.